From left to right: Dr. Andrea Vethencourt (clinical researcher in the Transformation and Metastasis Group at IDIBELL and the CNIO, and oncologist at ICO); Dr. Eva González-Suarez (leader of the ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Denosumab may reduce fracture risk, but increase cardiovascular risks in patients on dialysis. Denosumab may reduce fracture risk better than oral bisphosphonates for treatment of osteoporosis in ...

Denosumab use was associated with a lower risk for incident diabetes among patients with osteoporosis. Denosumab use is associated with a lower risk for diabetes among patients with osteoporosis, ...

Please provide your email address to receive an email when new articles are posted on . The denosumab and placebo groups had an estimated difference of 8.9 in the Ghent University Scoring System at 24 ...

Findings from a phase 3 trial showed denosumab-dssb had comparable efficacy, safety, immunogenicity, PK and PD to Prolia in patients with postmenopausal osteoporosis. Ospomyv is approved to treat ...